Uscom Achieves First Cash Flow Positive Quarter
April 19th, 2017
Record cash receipts – $1.41M (up 41%)
New Uscom Euro Grant for Pulmonary Research
April 3rd, 2017
“Incentive based smart spacer to promote pulmonary recovery training & drug uptake”
Uscom has announced the award of a second European scientific research grant to Uscom Europe based in Budapest. Uscom was a member of a consortium awarded 1,317,502 Euro (≈AU$1.86) over 2 years to develop a new smart spacer and software to promote pulmonary recovery training and drug uptake under the Eurostars programme. The total value of the project is 1,317,502 Euro (AU$1.86) and Uscom will receive 349,480k Euro (≈AU$492k) over the next 2 years ($246k AUD pa).
The project is titled “Incentive based smart spacer to promote pulmonary recovery training & drug uptake” (NEMZ_16-1-2017-0001) and focuses on the development of a new medical device that increases the efficiency of drug delivery from inhalation dispensers, supported by software to re-inforce the appropriate on going use of medication. Uscom’s advanced digital multi-path ultrasonic technology is already being adopted among cloud based telemetric pulmonary monitoring companies in the USA, while the sophisticated SpiroReporter archiving and analysis software which can be installed on smart phones, tablets, computers or the cloud provides opportunities to combine complex pulmonary function measurements with a remote digital monitoring platform.
While many new companies are marketing simple inhaler trackers connected to an app or software, the SpiroSonic tSpiro solution provides comprehensive pulmonary function monitoring of patients in their own home, with full cloud based telemetric analysis, diagnosis and management which generates “big data” for population disease profiling. Uscom’s contribution to this project is derived from experience in researching, developing and manufacturing world leading digital ultrasonic spirometers and digital respiratory monitoring technologies.
Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Hundreds of millions of people around the world suffer from preventable chronic respiratory diseases, and this research funding focuses on solving a clinical problem that results in hundreds of thousands of deaths per year. This grant is recognition that Uscom has a global reputation for R&D and manufacturing of innovative cardiovascular and pulmonary monitoring devices, and the development of clinical solutions to drive improved global pulmonary care.”
The Eurostars programme is a joint programme by Eureka and the European Commission which is co-funded from the national budgets or 36 participating states and countries. The Hungarian National Research, Development and Innovation Office as part of the European Research Organisation administers the grant.
The entire grant project is a collaboration of Uscom Europe with a group of Dutch pulmonary specialists at Stichting Gelre Ziekenhuizen and SilverFit B.V. (The Dutch Foundation for the Elderly), and is planned to produce Uscom owned IP and products. This grant is in addition to the prior Hungarian grant of $427K AUD announced – Nov 28th 2016.
Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD and sleep disorders. The devices and technologies are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD diagnosis and medication monitoring.
New USCOM Evidence for Pre-eclampsia
March 30th, 2017
New evidence supports USCOM 1A screening and improved outcomes during pregnancy
Uscom has announced the publication of two new peer reviewed papers confirming the effectiveness of USCOM 1A for diagnosing pre-eclampsia and guiding hypertensive therapy in pregnancy. The publications were in the prestigious Ultrasound in Obstetrics and Gynaecology and authored by obstetrics and gynaecology specialists and researchers from the University of Rome, Rome, the Policlinico, Rome, and the St George’s Hospital, London.
Professor Valensise and his team from the Department of Obstetrics and Gynaecology at the University of Rome Tor Vergata and Professor Khalil and her group at St George’s Hospital London have been using and researching the USCOM 1A in pregnancy for pre-eclampsia for over 3 years.
Executive Chairman of Uscom, Associate Professor Rob Phillips said, “Science is value for Uscom shareholders and this science provides us with a new revenue platform as our business continues rapid growth of the back of important scientific achievement. These data demonstrate that the use of USCOM in pregnancy can improve maternal and foetal outcomes in pregnancy, and support USCOM 1A use as a routine screening monitor of maternal hemodynamics, from the initial examination up to, and during, delivery and should be considered as a standard of care for monitoring pregnancy.”
In the second study, “Nitric oxide (NO) donors and haemodynamic changes in fetal growth restriction”, 26 pregnant females with diagnosis of intrauterine growth restriction (IUGR) with 30 week gestational age foetuses, were enrolled. Their hemodynamics were monitored with USCOM 1A during treatment with transdermal nitric oxide donors (glycerine trinitrate). Nitric oxide acts on the placental to dilate the placental vessels and ensure adequate perfusion and oxygen supply to the growing foetus to ensure optimal development. The hemodynamics from these patients were then compared to an untreated, case matched, 26 patient cohort. The mothers with IUGR and NO donor treatment had significantly improved USCOM measured maternal hemodynamics, and had babies with significantly increased birth weight. The study concluded “……our results might open new perspectives in the treatment of fetal growth restriction, focusing on main maternal cardiovascular anomalies.”